Atrial Fibrillation Clinical Research Trials

Birmingham : 1160.128.1046 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Birmingham : University of Alabama at Birmingham

Clarification of Optimal Anticoagulation Through Genetics

Birmingham : University of Alabama at Birmingham

Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study

Birmingham : University of Alabama, Birmingham

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Birminham : University of Alabama, Birmingham

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Gulf Shores : 1160.129.32023 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Huntsville : 1160.128.1045 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Mobile : 1160.128.1003 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Pell City : 1160.129.32172 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Scottsboro : 1160.129.32054 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tuscaloosa : 1160.129.32174 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Jonesboro : 1160.129.32150 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hot Springs : 1160.129.32156 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lake Havasu City : 1160.129.32151 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Phoenix : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Phoenix : AZ Heart Rhythm Center

CARTO® 3 System and Real Time Intracardiac Ultrasound

Phoenix : Arizona Heart Rhythm Research Center

Continued Access to PREVAIL (CAP2)

Phoenix : 1160.129.32250 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Phoenix : Heart Rhythm Specialists PC

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Phoenixville : 1160.129.32159 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hot Springs : 1160.128.1067 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hot Springs : 1160.129.32140 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Little Rock : Arkansas Cardiology, PA Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Little Rock : 1160.129.32009 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Little Rock : 1160.129.32014 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Santa Ana : Coastal Multi-Specialty Research

Cardiovascular outcomes study to evaluate the potential to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event & type II diabetes mellitus.

Santa Ana : Coastal Multi-Specialty Research

Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

Santa Ana : Coastal Multi-Specialty Research

RESCUE cardiovascular clinical trial

Beverly Hills : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Encinitas : 1160.129.32035 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Fresno : 1160.129.32019 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hollywood : 1160.129.32230 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

La Jolla : 1160.129.32225 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

La Mesa : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

La Mesa : 1160.129.32216 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Los Alamitos : 1160.129.32039 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Los Angeles : Ronald Reagan UCLA Medical Center

ABLATE AF Registry Trial

Los Angeles : Good Samaritan Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Merced : 1160.129.32043 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

National City : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Orange : Orange County Heart Institute and Research Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Palo Alto : Stanford Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Rancho Mirage : 1160.129.32170 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sacramento : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Sacramento : Regional Cardiology Associates

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Sacramento : Regional Cardiology Associates, Mercy General Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Sacramento : UC Davis Medical Center

Ventricular Rate Regularization for Improved Quality of Life in Patients With CHF and AF

San Diego : 1160.128.1042 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

San Diego : University of California San Diego Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

San Diego : 1160.129.32017 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

San Francisco : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

San Francisco : University of California at San Francisco Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

San Francisco : University of California San Francisco

Clarification of Optimal Anticoagulation Through Genetics

San Francisco : UCSF

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

San Jose : Good Samaritan Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Sana Ana : 1160.129.32051 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Santa Monica : Pacific Heart Institute

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Stanford : Stanford University Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Stanford : Stanford University Medical Center

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study ( Staged DEEP)

Stanford : Stanford University School of Medicine

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Stanford : Stanford Univeristy Medical Center

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Stockton : 1160.129.32102 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tarzana : Heart Rythm Specialists of Southern California Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Temecula : 1160.129.32167 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32205 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32196 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32249 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Visalia : 1160.129.32104 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Aurora : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Aurora : The Medical Center of Aurora Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Aurora : Aurora Denver Cardiology Associates

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Aurora : 1160.129.32031 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Colorado Spring : 1160.128.1005 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Colorado Springs : Penrose Saint Francis Health Services Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Colorado Springs : 1160.129.32021 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Colorado Springs : 1160.129.32204 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Denver : 1160.128.1023 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Denver : Colorado Heart and Vascular

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Bridgeport : 1160.128.1016 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Bridgeport : 1160.129.32193 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Bridgeport : 1160.129.32233 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Guilford : 1160.128.1018 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hartford : Hartford Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Milford : 1160.129.32008 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Norwalk : 1160.128.1050 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Norwalk : 1160.129.32074 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Shelton : 1160.129.32152 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Waterbury : 1160.128.1057 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Newark : 1160.129.32066 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Washington : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Washington : 1160.129.32202 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Washington DC : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Washington, D.C. : George Washington University Medical Faculty Associates Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Daytona Beach : Cardiology Research Associates

Atrial Fibrillation

Atlantis : JFK Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Bradenton :

REVEAL AF: Incidence of AF in High Risk Patients

Brandon : 1160.128.1032 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Brandon : 1160.129.32144 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Clearwater : 1160.129.32119 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Coral Springs : 1160.128.1021 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Daytona Beach : 1160.128.1027 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Daytona Beach : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Daytona Beach : Daytona Heart Group

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Delray Beach : 1160.129.32048 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Fort Lauderdale : Broward General Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Gainesville : University of Florida - Shands Hospital

ABLATE AF Registry Trial

Gainesville : University of Florida

Clarification of Optimal Anticoagulation Through Genetics

Gainesville : 1160.129.32132 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hollywood : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Hollywood : 1160.129.32128 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Jacksonville : 1160.128.1062 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Jacksonville : 1160.128.1019 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Jacksonville : Diagnostic Cardiology Associates PA

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Jacksonville : Mayo Clinic Jacksonville

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Jupiter : 1160.129.32090 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kissimmee : Osceola Regional Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Lakeland : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Lakeland : 1160.129.32079 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Largo : 1160.128.1054 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Miami : 1160.129.32094 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32222 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32018 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32076 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32124 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32212 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miramar Beach : 1160.129.32125 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New Smyrna Beach : 1160.129.32005 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Oakland Park : 1160.129.32147 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Orlando : 1160.128.1087 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Orlando : Florida Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Orlando : 1160.129.32182 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Orlando : Florida Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Pembroke Pines : 1160.129.32026 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Pembroke Pines : 1160.129.32063 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Pensacola : 1160.128.1058 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Pismo Beach : 1160.129.32136 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Port Charlotte : 1160.128.1007 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Port Charlotte : 1160.129.32208 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Rockledge : 1160.128.1060 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Saint Petersburg : 1160.129.32116 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Sarasota : 1160.129.32006 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : 1160.129.32248 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Seminole : 1160.129.32020 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St Petersburg : 1160.129.32213 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St. Petersburg : Northside Hospital and Heart Institute Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

St. Petersburg : 1160.129.32057 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tallahassee : Tallahassee Memorial Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tallahassee : 1160.129.32064 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tampa : Pepin Heart Hospital

ABLATE AF Registry Trial

Tampa : Florida Heart Rhythm-University of South Florida College of Medicine Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Venice : Venice Regional Medical Center

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Wellington : 1160.129.32037 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Atlanta : 1160.129.32178 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Atlanta : Emory University Hospital Midtown

Management of New-Onset Postoperative Atrial Fibrillation

Atlanta : Emory University Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Atlanta : Piedmont Heart Institute

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Augusta : Georgia Health Sciences University Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Augusta : Georgia Health Sciences University

Clarification of Optimal Anticoagulation Through Genetics

Cumming : 1160.129.32185 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Decatur : 1160.129.32083 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Macon : Georgia Arrhythmia Consultants & Research Institute Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Roswell : 1160.128.1068 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Coeur d' Alene : 1160.128.1076 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Coeurd'Alene : 1160.129.32096 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Barrington : Alexian Brothers Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Belleville : 1160.129.32071 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Chicago : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Chicago : Rush University Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Chicago : 1160.129.32044 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32065 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Chicago : Northwestern University

Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring

Evanston : NorthShore University Health System Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hinsdale : 1160.129.32117 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Maywood : Loyola University Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Maywood : Loyola University Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Maywood : Loyola University Chicago

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Melrose Park : 1160.128.1073 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Melrose Park : 1160.129.32003 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Morton : 1160.129.32133 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Springfield : Prairie Heart Institute

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Winfield : 1160.128.1048 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Bloomington : 1160.129.32106 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Brownsburg : 1160.129.32001 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hammond : 1160.129.32046 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Indianapolis : 1160.128.1029 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Indianapolis : Heart Center of Indiana

ABLATE AF Registry Trial

Indianapolis : St. Francis Heart Center

ABLATE AF Registry Trial

Indianapolis : Saint Vincent Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Muncie : Medical Consultants, P.C.

Ibutilide Administration During Pulmonary Vein Ablation

Ames : 1160.129.32042 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Waterloo : 1160.129.32055 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

West Des Moines : Mercy Medical Center-Iowa Heart Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

West Des Moines : 1160.129.32089 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kansas City : The Univ. of Kansas Hospital

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

Kansas City : The University of Kansas Medical Center

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Kansas City : University of Kansas Hospitals

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Overland Park : 1160.128.1079 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Overland Park : 1160.129.32029 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Bowling Green : 1160.129.32010 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Elizabeth : 1160.129.32025 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lexington : Central Baptist Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Lexington : Central Baptist Hospital

Continued Access to PREVAIL (CAP2)

Lexington : Central Baptist Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Lexington : Central Baptist Hospital

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Owensboro : 1160.129.32059 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Alexandria : 1160.129.32176 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Baton Rouge : 1160.128.1008 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Bossier City : 1160.129.32201 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hammond : 1160.129.32045 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lafayette : 1160.129.32056 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lake Charles : 1160.129.32169 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lake Charles : 1160.129.32235 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New Orleans : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

New Orleans : Tulane University Health Science Center

Clarification of Optimal Anticoagulation Through Genetics

Slidell : 1160.129.32164 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Auburn : 1160.128.1025 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Biddeford : 1160.129.32122 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Annapolis : 1160.129.32226 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Baltimore : Johns Hopkins Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Baltimore : University of Maryland School of Medicine

Clarification of Optimal Anticoagulation Through Genetics

Baltimore : 1160.129.32228 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Baltimore : Johns Hopkins Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Baltimore : University of Maryland

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Baltimore : Johns Hopkins

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Baltimore : Johns Hopkins Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Glen Burnie : 1160.129.32247 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Salisbury : 1160.128.1012 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Salisbury : 1160.129.32148 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Salisbury : 1160.129.32155 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Silver Spring : Washington Adventist Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Takoma Park : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Takoma Park : Washington Adventist Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Towson : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Towson : 1160.129.32229 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ayer : 1160.129.32203 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Boston : Brigham and Womens Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Boston : Massachusetts General Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Boston : Brigham and Women's Hospital

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Boston : Beth Israel Deaconess Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Boston : Brigham and Women's Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Boston : Massachusetts General Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Boston : Brigham and Women's Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Boston : Massachusetts General Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Fall River : 1160.129.32013 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Worcester : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Alpena : 1160.129.32036 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ann Arbor : University of Michigan Cardiovascular Center

Effects of Fish Oil on Post Ablation Arrhythmias

Bay City : 1160.129.32234 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Detroit : Henry Ford Hospital

Clarification of Optimal Anticoagulation Through Genetics

Flint : 1160.129.32047 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Grand Blanc : 1160.129.32168 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Grand Rapids : Spectrum Health

ABLATE AF Registry Trial

Grand Rapids : Spectrum Health

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Lansing : Thoracic & Cardiovascular Healthcare Foundation

ABLATE AF Registry Trial

Lansing : 1160.129.32052 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Marquette : 1160.129.32142 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Mount Clemens : 1160.129.32232 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Muskegon : 1160.128.1017 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Niles : 1160.129.32053 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Rochester : 1160.129.32134 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Rochester Hills : 1160.128.1015 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Royal Oak : Beaumont Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Royal Oak : William Beaumont Hospital

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Saginaw : 1160.129.32231 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Saginaw : 1160.129.32075 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Southfield : Providence Hospital

AMPLATZER Cardiac Plug Clinical Trial

Traverse City : Munson Medical Center

ABLATE AF Registry Trial

Troy : William Beaumont Hospital

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Ypsilanti : Saint Joseph Mercy Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Chaska : 1160.129.32024 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Minneapolis : Minneapolis V.A. Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Minneapolis : Park Nicollet Institute

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Minneapolis : Abbott Northwestern Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Rochester : Mayo Clinic Rochester Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Rochester : Mayo Clinic College of Medicine

Clarification of Optimal Anticoagulation Through Genetics

Rochester : Mayo Clinic Rochester/St. Mary's Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Rochester : Mayo Clinic

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Saint Paul : HealthEast St. Joseph's Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

St Cloud : 1160.129.32190 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St. Louis Park : Park Nicollet Methodist Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tupelo : 1160.128.1004 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Columbia : 1160.128.1014 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kansas City : 1160.128.1047 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kansas City : Mid-America Heart Institute

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

St Louis : 1160.129.32184 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : Washington University/Barnes Jewish Hospital

ABLATE AF Registry Trial

St. Louis : Saint John's Mercy Heart Health Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

St. Louis : Washington University School of Medicine

Clarification of Optimal Anticoagulation Through Genetics

St. Louis : 1160.129.32143 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : 1160.129.32101 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Great Falls : 1160.128.1069 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kalispell : 1160.128.1011 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kalispell : 1160.129.32165 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Missoula : The International Heart Institute of Montana Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Lincoln : Nebraska Heart Hospital

ABLATE AF Registry Trial

Omaha : 1160.128.1059 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Papillion : 1160.129.32199 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Henderson : Cardiovascular Consultants of Nevada

Safety of Amiodarone and Ranolazine Together in Patients With Angina

Las Vegas : Cardiovascular Consultants of Nevada

Safety of Amiodarone and Ranolazine Together in Patients With Angina

Reno : 1160.129.32180 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Bridgewater : 1160.129.32154 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Camden : Cooper University Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Elmer : 1160.128.1039 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Englewood : 1160.129.32181 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Flemington : 1160.128.1035 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hackensack : Hackensack University Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Haddon Heights : 1160.129.32179 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hammonton : 1160.129.32198 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Linden : 1160.129.32030 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Neptune : 1160.129.32049 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

News Brunswick : Robert Wood Johnson University Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Ocean : 1160.129.32242 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ridgewood : Valley Health System

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

Ridgewood : The Valley Hospital

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Ridgewood : 1160.129.32221 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ridgewood : The Valley Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Somerset : 1160.129.32099 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

South Plainfield : 1160.129.32007 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Voorhees : 1160.129.32069 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Albuquerque : 1160.128.1036 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

New York : Biomedical Research Alliance of New York

Paroxysmal Atrial Fibrillation (PAF)

Albany : Albany Associates in Cardiology Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bronx : Montefiore Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bronx : Montefiore Medical Center

Clarification of Optimal Anticoagulation Through Genetics

Bronxville : 1160.129.32084 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Brooklyn : 1160.129.32246 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Buffalo : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Flushing :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Hawthorne : 1160.128.1063 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Huntington : 1160.129.32195 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Mineola : 1160.128.1078 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Mineola : 1160.129.32038 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New York : 1160.128.1083 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

New York : Columbia University Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

New York : New York University Langone Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

New York : Mount Sinai School of Medicine

Clarification of Optimal Anticoagulation Through Genetics

New York : Mount Sinai Medical Center

Continued Access to PREVAIL (CAP2)

New York : Mount Sinai School of Medicine

Deviating the Esophagus in Atrial Fibrillation Ablation

New York : 1160.129.32110 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New York : Mount Sinai School of Medicine

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

New York : St. Luke's Roosevelt Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

New York : Mount Sinai Medical Center

TOCCASTAR - TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation

NY : Mt. Sinai Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Poughkeepsie : 1160.128.1001 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Rochester : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Rochester : University of Rochester Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Staten Island : Staten Island University Hosptial

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

Stony Brook : Stony Brook University Hospital and Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Stony Brook : Stony Brook Univeristy Medical Center

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Syracuse : 1160.129.32015 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Syracuse : 1160.129.32139 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Utica : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Utica : Mohawk Valley Heart Institute / St. Elizabeth Medical Center

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

Williamsville : 1160.129.32016 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Williamsville : 1160.129.32209 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Asheboro : 1160.129.32194 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Asheville : 1160.128.1022 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Chapel Hill : University of North Carolina at Chapel Hill Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Charlotte : The Sanger Clinic, PA Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Charlotte : Carolinas Medical Center/Sanger Heart & Vascular

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Durham : Duke University Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Durham : Duke University

Clarification of Optimal Anticoagulation Through Genetics

Durham : Duke University Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Durham : Duke University

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Durham : Duke University Medical Center

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Durham : Duke University Health System

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Gastonia : 1160.128.1052 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Greensboro : 1160.129.32022 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hickory : 1160.129.32070 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

High Point : 1160.129.32033 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Jacksonville : 1160.129.32114 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lenoir : 1160.129.32072 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Pinehurst : 1160.129.32073 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Raleigh : 1160.129.32162 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Statesville : 1160.128.1071 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Wilson : 1160.129.32215 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Winston-Salem : Wake Forest University Health Sciences Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Fargo : 1160.129.32118 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Minot : 1160.129.32220 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Cincinnati : Good Samaritan Hospital

ABLATE AF Registry Trial

Cincinnati : University of Cincinnati Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cincinnati : Medisync Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cincinnati : Bethesda North Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Cincinnati : Bethesda North Hospital l TriHealth Hatton Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Cleveland : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Cleveland : Cleveland Clinic Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cleveland : Cleveland Clinic Foundation

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Cleveland : Cleveland Clinic

Siemens 3-D C-Arm CT of the Heart Chambers

Cleveland : Cleveland Clinic Foundation

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Columbus : Ohio State University Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Columbus : The Ohio State University

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Columbus : Ohio State University

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Columbus : Ohio State University

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Fairview Park : 1160.129.32061 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Gallipolis : 1160.129.32011 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hudson : 1160.129.32060 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kettering : 1160.129.32183 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Marion : 1160.129.32158 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miamisburg : 1160.129.32012 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Springfield : 1160.129.32244 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toledo : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Toledo : University of Toledo Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Youngstown : 1160.129.32032 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Oklahoma City : Oklahoma Heart Hospital

ABLATE AF Registry Trial

Oklahoma City : University of Oklahoma

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Oklahoma City : OU Medical Center

Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

Oklahoma City : University of Oklahoma

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Tulsa : Oklahoma Heart Institute Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tulsa : Oklahoma Heart Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Bend : 1160.128.1053 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hillsboro : 1160.128.1033 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Portland : Providence Saint Vincent Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Portland : Oregon Health and Science University Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Portland : 1160.129.32163 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Portland : Providence Heart and Vascular Institute

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Altoona : 1160.128.1037 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Camp Hill : 1160.128.1034 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Camp Hill : 1160.129.32236 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Camp Hill : Capital Cardiovascular Associates

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Carnegie : 1160.129.32086 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Chambersburg : 1160.129.32206 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Danville : Geisinger Wyoming Valley Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Doylestown : Doylestown Cardiology Associates/Central Bucks

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Doylestown : 1160.129.32157 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Doylestown : Doylestown Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Doylestown : Doylestown Cardiology Associates

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Harleysville : 1160.129.32113 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Harrisburg : Pinnacle Health

ABLATE AF Registry Trial

Harrisburg : Pinnacle Health

ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal AF

Hershey : Penn State University Cardiovascular Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Jersey Shore : 1160.129.32127 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lancaster : Lancaster Heart & Stroke Foundation

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Lancaster : Lancaster Heart & Stroke

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Langhorne : 1160.128.1010 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Lansdale : 1160.129.32153 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

North Wales : Call for Information

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Penndel : 1160.129.32115 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Philadelphia : University of Pennsylvania Health System Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Philadelphia : Drexel University College of Medicine Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Philadelphia : Hospital of the University of Pennsylvania

Clarification of Optimal Anticoagulation Through Genetics

Philadelphia : Hospital of the University of Pennsylvania

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Philadelphia : Hospital of the University of Pennsylvania

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Philadelphia : Hospital of the University of Pennsylvania

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Philadelphia : University of Pennslyvania

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Pittsburgh : 1160.128.1056 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Pittsburgh : V.A. Pittsburgh Healthcare System Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Pittsburgh : University of Pittsburgh Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Sayre : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Uniontown : 1160.128.1065 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Warminster : 1160.129.32109 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Wynnewood : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Wynnewood : Lankenau Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Yardley : 1160.129.32137 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Mt Pleasant : PMG Research of Charleston Updated

Research Study Enrolling Participants With Atrial Fibrillation.

Anderson : 1160.129.32160 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Anderson : 1160.129.32243 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Beaufort : 1160.129.32002 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Charleston : 1160.128.1043 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Charleston : Medical University of South Carolina

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Charleston : Medical University South Carolina

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Columbia : Sisters of Charity, Providence Hospital

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

Columbia : 1160.129.32050 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Greenville : Greenville Memorial Hospital

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Myrtle Beach : 1160.129.32108 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Rapid City : 1160.128.1040 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Chatanooga : 1160.129.32217 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Knoxville : 1160.129.32080 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Knoxville : 1160.129.32082 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Memphis : Baptist Memorial Hospital

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Nashville : Vanderbilt University Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Nashville : Vanderbilt University

Clarification of Optimal Anticoagulation Through Genetics

Nashville : St. Thomas Research Institute

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Nashville : Vanderbilt Heart Institute

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study ( Staged DEEP)

Nashville : 1160.129.32186 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Nashville : Saint Thomas Research Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

New Tazewell : 1160.129.32223 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : DM Clinical Research

Atrial Fibrillation - Houston, TX

Austin : Texas Cardiac Arrhythmia Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Austin : 1160.129.32145 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Austin : Austin Heart PA

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Austin : Texas Cardiac Arrhythmia Research Foundation

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Austin : Texas Cardiac Arrhythmia Foundation

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Austin : Texas Cardiac Arrhythmia Research Foundation (TCARF)

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Austin : Texas Cardiac Arrhythmia Institute

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Beaumont : 1160.129.32095 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Dallas : Baylor Heart and Vascular Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Dallas : University of Texas Southwestern Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Dallas : Baylor Heart and Vascular

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Dallas : Baylor Research Institute

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Fort Worth : Baylor All Saints Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Fort Worth : 1160.129.32097 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Fort Worth : Plaza Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Galveston : University of Texas Medical Branch

Clarification of Optimal Anticoagulation Through Genetics

Grapevine : 1160.129.32105 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Houston : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Houston : University of Texas Health Science Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Houston : 1160.129.32092 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32027 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32100 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32111 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32123 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : Methodist Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Houston : Houston Methodist

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Humble : 1160.129.32219 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Katy : 1160.129.32171 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Killeen : 1160.128.1006 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kingwood : 1160.129.32211 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

McKinney : 1160.128.1061 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

New Braunfels : 1160.129.32189 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

North Richland Hills : 1160.129.32177 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Odessa : 1160.129.32197 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Plano : The Heart Hospital Baylor Plano Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Plano : Baylor Research Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

San Antonio : 1160.128.1082 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

San Antonio : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

San Antonio : South Texas Cardiovascular Consultants Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

San Antonio : 1160.129.32187 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Seguin : 1160.129.32191 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sugar Land : 1160.129.32040 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sugar Land : 1160.129.32068 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Temple : Scott and White Memorial Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tomball : 1160.129.32091 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Waco : 1160.129.32093 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Whitney : 1160.129.32175 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Bountiful : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Murray : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Murray : Intermountain Medical Center

Clarification of Optimal Anticoagulation Through Genetics

Murray : Intermountain Medical Center

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Salt Lake City : St. Mark's

ABLATE AF Registry Trial

Salt Lake City : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Salt Lake City : Intermountain Medical Center-LDS Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Salt Lake City : University of Utah Health Care

Clarification of Optimal Anticoagulation Through Genetics

Salt Lake City : 1160.129.32034 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Salt Lake City : 1160.129.32121 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Burke : 1160.129.32166 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Charlottesville : University of Virginia Health System Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Charlottesville : University Of Virginia Health System

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Charlottesville : University of Virginia Health System

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Charlottesville : Univeristy of Virginia

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Chesapeake : 1160.129.32004 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Danville : 1160.128.1077 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Danville : 1160.129.32067 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Fairfax : Inova Fairfax Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Falls Church : 1160.128.1064 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Falls Church : Fairfax Hospital, Department of Cardiovascular and Thoracic Surgery

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

Falls Church : 1160.129.32146 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Falls Church : Virginia Heart

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Manassas : 1160.129.32200 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Norfolk : Sentara Norfolk General Hospital

ABLATE AF Registry Trial

Norfolk : Sentara Norfolk General Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Norfolk : Sentara Norfolk Hospital

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study ( Staged DEEP)

Norfolk : Sentara Cardiovascular Research Institute

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Richmond : University of Virginia Commonwealth/Medical College of Virginia

ABLATE AF Registry Trial

Richmond : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Richmond : Virginia Commonwealth University Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Richmond : Virginia Commonwealth University

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Richmond : Virginia Commonwealth University

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Burien : 1160.129.32062 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Port Orchard : 1160.129.32227 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Seattle : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Seattle : Swedish Medical Center

ABLATE AF Registry Trial

Seattle : Swedish Medical Center - Providence Campus Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Seattle : University of Washington Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Seattle : 1160.129.32241 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tacoma : Cardiac Study Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Huntington : 1160.129.32028 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Marshfield : Marshfield Clinical Research Foundation

Clarification of Optimal Anticoagulation Through Genetics

Milwaukee : Aurora Saint Lukes Medical Center Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Milwaukee : Aurora St. Luke's Medical Center

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

Milwaukee : 1160.129.32041 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : 1160.129.32088 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : 1160.129.32058 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : St. Luke's Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Wausau : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Wausau : Aspirus Wausau Hospital

ABLATE AF Registry Trial

Wausau : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Buenos Aires : 1160.129.21008 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Adelaide : Royal Adelaide Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Adelaide : Royal Adelaide Hospital Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Herston : Royal Brisbane and Women's Hospital Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Parkville : Royal Melbourne Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Parkville : Royal Adelaide Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Westmead : Westmead Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Westworthville : Westmead Hospital Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Graz : LKH/Uniklinikum - Klinische Abteilung für Kardiologie

Graz Study on the Risk of Atrial Fibrillation

Graz : Marianne Brodmann

Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation

Linz : A. ö. Krankenhaus der Elisabethinen Linz Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Wien : Allgemeines Krankenhaus der Stadt Wien Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Antwerpen : AZ Middelheim

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Bonheiden : Imelda Ziekenhuis

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Brugge : A.Z. St Jan AV

Atrial Fibrillation Progression Trial

Brugge : AZ St Jan, Cardiologie

REVOLUTION (WFCC-133)

Ghent : Drug Research Unit Ghent

A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.

Gilly : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Leuven : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Liege : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

MOL : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Belo Horizonte : 1160.129.22012 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Belo Horizonte : 1160.129.22011 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Blumenau : 1160.129.22029 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sao Jose do Rio Preto : 1160.129.22001 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sao Paulo : Hospital Sao Paulo Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Sao Paulo : 1160.129.22008 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tatui : 1160.129.22032 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Votuporanga : 1160.129.22025 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Antigonish : 1160.129.06010 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Calgary : University of Calgary Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Calgary : 1160.129.06018 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Calgary : University of Calgary, Foothills Hospital

Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins

Cambridge : 1160.129.06023 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Chicoutimi : 1160.129.06024 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Coquitlam : 1160.129.06005 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Downsview : 1160.129.06003 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Edmonton : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Edmonton : 1160.129.06004 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Edmonton : Royal Alexandra Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Grimsby : 1160.129.06020 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Halifax : 1160.129.06025 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hamilton : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hamilton : 1160.129.06016 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hamilton : 1160.129.06032 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kelowna : 1160.129.06027 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kingston : Kingston General Hospital

Incidence of Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study

Levis : 1160.129.06014 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

London : London Health Sciences Center

DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation

MIssissauga : 1160.129.06028 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Montreal : 1160.129.06009 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Montreal : Montreal Heart Institute (Institut de Cardiologie de Montreal)

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Newmarket : Southlake Regional Health Centre

Efficiency Study Evaluating the Use of the PVAC Catheter Technology for Performing Ablation in Patients With Atrial Fibrillation

Newmarket : Southlake Regional Health Center

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Oakville : 1160.129.06017 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Oshawa : 1160.129.06001 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Quebec : Institut Universitaire de Cardiologie et de Pneumologie de Québec

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Québec : 1160.129.06006 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Richmond : 1160.129.06034 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sainte-Foy : 1160.129.06022 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Saskatoon : 1160.129.06002 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St. John's : 1160.129.06007 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St-Jean-sur-Richel : 1160.129.06030 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06026 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06029 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06031 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toronto : Sunnybrook Health Sciences Centre

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Vancouver : Saint Pauls Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Vancouver : St. Paul's Hospital

Measurement of Left and Right Atria From CT Scans of Cardiac Rhythm Disorder Cases

Victoria : 1160.129.06021 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Victoria : Victoria Cardiac Arrhythmia Trials Inc

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Beijing : Beijing Anzhen Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Beijing : Fuwai Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Guangzhou : Guangdong Provincial People's Hospital Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Nanjing : First Affiliated Hospital of Nanjing Medical University Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bogotá : 1160.129.24006 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Prague 4 : IKEM

Evaluation of a New Cardiac Pacemaker

Prague 5 : Na Homolce Hospital

Evaluation of a New Cardiac Pacemaker

Hellerup : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Herning : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

København NV : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Viborg : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Tallin : 1160.136.38001 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Lappeenranta : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Oulu : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Pori : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Turku : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Vaasa : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Abbeville : CHG

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Antony : Hopital Privé

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Arras : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Auxerre : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Avignon : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Bordeaux : Clinique de Bordeaux Cauderan

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Caen : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Castres : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Clamart : HIA Percy

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Dinan : CH René Pleven

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Dole : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Dunkerque : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Evreux : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Grenoble : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Grenoble : CHU Grenoble

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Le Chesnay : CMC Parly II

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Le Havre : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Lille : CHU Lille

European Carto XP Registry for Validating Specialized CFAE Software

Lille Cedex : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Limoges : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Lomme : CH Saint Philibert

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Marseille : Hôpital La Timone

Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.

Marseille : Clinique de la Casamance

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Marseille : CHU La Timone

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Marseille : Clinique Bouchard

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Marseille : Hopital Saint Joseph

European Carto XP Registry for Validating Specialized CFAE Software

Martigues : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Metz : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Montpellier : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Montpellier : CHU Arnaud de Villeneuve

European Carto XP Registry for Validating Specialized CFAE Software

Mulhouse : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Nancy : CHU Hôpital de Brabois

European Carto XP Registry for Validating Specialized CFAE Software

Nancy : HDB CHU de Nancy

REVOLUTION (WFCC-133)

Nantes : CHU Nantes

European Carto XP Registry for Validating Specialized CFAE Software

Neuilly : Ambroise Paré

European Carto XP Registry for Validating Specialized CFAE Software

Neuilly sur Seine : Clinique Ambroise Paré

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Nimes : Hopital Les Franciscaines

European Carto XP Registry for Validating Specialized CFAE Software

Paris cedex 13 : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Pessac : Hopital Cardiologique du Haut Leveque

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Quincy-sous-Sénart : Hopital Privé Claude Galien

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rennes : Polyclinique Saint Laurent

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rennes : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rennes : CHU de Rennes

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Rouen : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rouen : University Hospital of Rouen

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Saint Etienne : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Saint Laurent du Var : Institut Arnalt Tzanck

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Saint-etienne : CHU de Saint-Etienne

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

Schiltigheim : CMCO

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Thionville : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Toulon : CH Toulon

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Toulouse : Clinique Pasteur

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Toulouse : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Valenciennes : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Aachen : Boehringer Ingelheim Investigational Site 593

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aachen : Boehringer Ingelheim Investigational Site 607

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aachen : Boehringer Ingelheim Investigational Site 608

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aachen : Boehringer Ingelheim Investigational Site 592

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aalen : Boehringer Ingelheim Investigational Site 147

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aalen : Boehringer Ingelheim Investigational Site 150

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aarbergen : Boehringer Ingelheim Investigational Site 447

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 791

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 795

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 817

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 812

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus-Alstaette : Boehringer Ingelheim Investigational Site 803

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahrensburg : Boehringer Ingelheim Investigational Site 1103

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aichtal : Boehringer Ingelheim Investigational Site 160

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aichtal : Boehringer Ingelheim Investigational Site 169

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albersloh : Boehringer Ingelheim Investigational Site 859

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt : Boehringer Ingelheim Investigational Site 79

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt : Boehringer Ingelheim Investigational Site 75

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt : Boehringer Ingelheim Investigational Site 95

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt-Ebingen : Boehringer Ingelheim Investigational Site 92

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alfeld : Boehringer Ingelheim Investigational Site 913

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alfter : Boehringer Ingelheim Investigational Site 633

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Allersberg : Boehringer Ingelheim Investigational Site 200

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alpenrod : Boehringer Ingelheim Investigational Site 448

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenburg : Boehringer Ingelheim Investigational Site 1212

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenburg : Boehringer Ingelheim Investigational Site 1190

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenburg : Boehringer Ingelheim Investigational Site 1191

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenholz : Boehringer Ingelheim Investigational Site 1109

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenholz : Boehringer Ingelheim Investigational Site 1080

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenstadt : Boehringer Ingelheim Investigational Site 512

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altlussheim : Boehringer Ingelheim Investigational Site 137

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alzenau : Boehringer Ingelheim Investigational Site 214

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alzenau : Boehringer Ingelheim Investigational Site 217

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alzenau : Boehringer Ingelheim Investigational Site 215

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Amberg : Boehringer Ingelheim Investigational Site 331

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Amberg : Boehringer Ingelheim Investigational Site 345

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Amberg : Boehringer Ingelheim Investigational Site 334

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Anderbeck : Boehringer Ingelheim Investigational Site 1308

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Apolda : Boehringer Ingelheim Investigational Site 1178

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Apolda : Boehringer Ingelheim Investigational Site 1170

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arenshausen : Boehringer Ingelheim Investigational Site 1162

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arnsberg : Boehringer Ingelheim Investigational Site 779

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arnstadt : Boehringer Ingelheim Investigational Site 1169

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arnstadt : Boehringer Ingelheim Investigational Site 1167

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Attendorn : Boehringer Ingelheim Investigational Site 751

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Attenkirchen : Boehringer Ingelheim Investigational Site 281

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Au am Rhein : Boehringer Ingelheim Investigational Site 12

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aue : Boehringer Ingelheim Investigational Site 1206

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 312

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 287

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 288

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 291

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 300

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 311

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Bederkesa : Boehringer Ingelheim Investigational Site 1030

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Bentheim : Boehringer Ingelheim Investigational Site 986

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Breisig : Boehringer Ingelheim Investigational Site 453

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Driburg : Boehringer Ingelheim Investigational Site 764

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Elster : Boehringer Ingelheim Investigational Site 1211

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ems : Boehringer Ingelheim Investigational Site 432

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ems : Boehringer Ingelheim Investigational Site 418

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ems : Boehringer Ingelheim Investigational Site 419

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Friedrichshall : Boehringer Ingelheim Investigational Site 129

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Homburg v.d.H. : Boehringer Ingelheim Investigational Site 500

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Homburg v.d.H. : Boehringer Ingelheim Investigational Site 502

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Homburg v.d.H. : Boehringer Ingelheim Investigational Site 501

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Klosterlausnitz : Boehringer Ingelheim Investigational Site 1194

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Kreuznach : Boehringer Ingelheim Investigational Site 422

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Krozingen : Herz-Zentrum

A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy

Bad Krozingen : Universitäts-Herzzentrum Freiburg - Bad Krozingen Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Bad Krozingen : Herzzentrum Bad Krozingen, Elektrophysiologie

Ventricular Pacing Site Selection (V-PASS)

Bad Langensalza : Boehringer Ingelheim Investigational Site 1149

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 891

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 893

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 896

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Muenstereifel : Boehringer Ingelheim Investigational Site 645

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Bad Nauheim : Kerckhoff-Klinik gGmbH Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Bad Nauheim : Kerckhoff Klinik Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bad Nauheim : Boehringer Ingelheim Investigational Site 498

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim : Boehringer Ingelheim Investigational Site 499

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim : Boehringer Ingelheim Investigational Site 429

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim : Boehringer Ingelheim Investigational Site 430

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Neuenahr : Boehringer Ingelheim Investigational Site 424

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Neustadt : Boehringer Ingelheim Investigational Site 213

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Neustadt/Saale : Herz- und Gefäß-Klinik

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Bad Neustadt/Saale : Klinik für Kardiologie II mit interventioneller Elektrophysiologie

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Bad Oeynhausen : Herz- und Diabeteszentrum Nordrhein-Westfalen Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Bad Oeynhausen : Herz -und Diabeteszentrum

DEtermining Accuracy and TrEnding CharacTerization of AF

Bad Oeynhausen : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Bad Pyrmont : Boehringer Ingelheim Investigational Site 944

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Reichenhall : Boehringer Ingelheim Investigational Site 240

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Reichenhall : Boehringer Ingelheim Investigational Site 241

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Sachsa : Boehringer Ingelheim Investigational Site 894

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Sachsa : Boehringer Ingelheim Investigational Site 895

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Saeckingen : Boehringer Ingelheim Investigational Site 19

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzuflen : Boehringer Ingelheim Investigational Site 833

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzuflen : Boehringer Ingelheim Investigational Site 849

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzungen : Boehringer Ingelheim Investigational Site 1152

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzungen : Boehringer Ingelheim Investigational Site 1164

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schussenried : Boehringer Ingelheim Investigational Site 85

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schussenried : Boehringer Ingelheim Investigational Site 84

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schwartau : Boehringer Ingelheim Investigational Site 1076

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Sulza : Boehringer Ingelheim Investigational Site 1174

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ueberkingen : Boehringer Ingelheim Investigational Site 98

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Waldsee : Boehringer Ingelheim Investigational Site 77

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wiesee : Boehringer Ingelheim Investigational Site 247

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wiessee : Boehringer Ingelheim Investigational Site 224

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wildbad : Boehringer Ingelheim Investigational Site 41

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wildbad : Boehringer Ingelheim Investigational Site 67

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Badel : Boehringer Ingelheim Investigational Site 1316

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baden hausen : Boehringer Ingelheim Investigational Site 920

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baden-Baden : Boehringer Ingelheim Investigational Site 3

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bamberg : Boehringer Ingelheim Investigational Site 1428

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bamberg : Boehringer Ingelheim Investigational Site 1434

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Barchfeld : Boehringer Ingelheim Investigational Site 1177

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bargteheide : Boehringer Ingelheim Investigational Site 1102

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Barssel/Harkebruegge : Boehringer Ingelheim Investigational Site 982

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baruth : Boehringer Ingelheim Investigational Site 1374

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bassum : Boehringer Ingelheim Investigational Site 930

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baumholder : Boehringer Ingelheim Investigational Site 421

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baumholder : Boehringer Ingelheim Investigational Site 426

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baunatal : Boehringer Ingelheim Investigational Site 538

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bautzen : Boehringer Ingelheim Investigational Site 1377

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bayreuth : Boehringer Ingelheim Investigational Site 359

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bechhofen : Boehringer Ingelheim Investigational Site 391

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beckum : Boehringer Ingelheim Investigational Site 842

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beckum : Boehringer Ingelheim Investigational Site 843

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beilrode : Boehringer Ingelheim Investigational Site 1400

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bellngries : Boehringer Ingelheim Investigational Site 208

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bendorf : Boehringer Ingelheim Investigational Site 441

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bensheim : Boehringer Ingelheim Investigational Site 460

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bensheim : Boehringer Ingelheim Investigational Site 487

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berg. Gladbach : Boehringer Ingelheim Investigational Site 867

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bergen : Boehringer Ingelheim Investigational Site 1140

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bergkamen-Ruenthe : Boehringer Ingelheim Investigational Site 775

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Universitätsmedizin Berlin - Charité Campus Virchow-Klinikum (CVK) Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Berlin : Vivantes-Klinikum am Urban Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Berlin : Charité Campus Virchow-Klinikum Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Berlin : Franz-Volhard-Klinik, Universitätsklinikum Charité Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Berlin : Charité Campus Mitte Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Berlin : Boehringer Ingelheim Investigational Site 369

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1222

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1224

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1225

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1214

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1215

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1229

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1329

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1330

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1348

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1349

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1248

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1249

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1253

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1257

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1261

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1262

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1264

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1265

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1268

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1270

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1271

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1272

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1278

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1318

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1323

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1325

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1326

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1327

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1328

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1331

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1347

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1280

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1260

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1263

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1267

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1273

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1246

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1247

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1251

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1252

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1254

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1258

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1221

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1223

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1226

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Berlin-Lankwitz : Boehringer Ingelheim Investigational Site 1220

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bernau : Boehringer Ingelheim Investigational Site 1250

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bernsdorf : Boehringer Ingelheim Investigational Site 1373

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beselich-Obertiefenbach : Boehringer Ingelheim Investigational Site 449

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beselich-Obertiefenbach : Boehringer Ingelheim Investigational Site 435

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bettingen : Boehringer Ingelheim Investigational Site 578

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beverungen : Boehringer Ingelheim Investigational Site 784

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biberach : Boehringer Ingelheim Investigational Site 76

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biblis : Boehringer Ingelheim Investigational Site 482

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biedenkopf : Boehringer Ingelheim Investigational Site 531

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biedenkopf : Boehringer Ingelheim Investigational Site 552

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bielefeld : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Bielefeld : Städtische Kliniken Bielefeld Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Bielefeld : Boehringer Ingelheim Investigational Site 860

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bielefeld : Boehringer Ingelheim Investigational Site 835

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bingen : Boehringer Ingelheim Investigational Site 91

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bischofferode : Boehringer Ingelheim Investigational Site 1160

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bischofsheim : Boehringer Ingelheim Investigational Site 474

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bismark : Boehringer Ingelheim Investigational Site 1317

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bispingen : Boehringer Ingelheim Investigational Site 1040

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bitterfeld : Boehringer Ingelheim Investigational Site 1312

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Blaubeuren : Boehringer Ingelheim Investigational Site 89

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Blomberg : Boehringer Ingelheim Investigational Site 855

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Blumberg : Boehringer Ingelheim Investigational Site 56

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bobritzsch : Boehringer Ingelheim Investigational Site 1361

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 740

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 741

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 742

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 736

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 738

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 734

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 732

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 743

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bodenkirchen : Boehringer Ingelheim Investigational Site 323

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boeblingen : Boehringer Ingelheim Investigational Site 47

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boeblingen : Boehringer Ingelheim Investigational Site 50

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boehlen : Boehringer Ingelheim Investigational Site 1397

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bonn : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Bonn : St. Marien Hospital Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Bonn : Boehringer Ingelheim Investigational Site 647

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bonndorf : Boehringer Ingelheim Investigational Site 54

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bonndorf : Boehringer Ingelheim Investigational Site 40

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boostedt : Boehringer Ingelheim Investigational Site 1088

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bopfingen : Boehringer Ingelheim Investigational Site 149

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bordesholm : Boehringer Ingelheim Investigational Site 1110

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Borgholzhausen : Boehringer Ingelheim Investigational Site 858

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Borken : Boehringer Ingelheim Investigational Site 805

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Borna : Boehringer Ingelheim Investigational Site 1416

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bottrop : Boehringer Ingelheim Investigational Site 799

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bovenden-Reyershausen : Boehringer Ingelheim Investigational Site 921

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braeunlingen : Boehringer Ingelheim Investigational Site 53

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Brake : Boehringer Ingelheim Investigational Site 966

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Brake : Boehringer Ingelheim Investigational Site 979

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bramsche : Boehringer Ingelheim Investigational Site 994

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunsbedra : Boehringer Ingelheim Investigational Site 1396

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 900

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 902

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 908

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 899

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Breitenguessbach : Boehringer Ingelheim Investigational Site 1436

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Zentralkrankenhaus Links der Weser, Siebels & Langes Partnerschaft Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Bremen : Boehringer Ingelheim Investigational Site 1017

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1020

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1021

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1022

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1023

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1025

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1009

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1018

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1019

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1024

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 1004

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 1001

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 1002

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 1034

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremervoerde : Boehringer Ingelheim Investigational Site 1006

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bretten : Boehringer Ingelheim Investigational Site 134

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Brilon : Boehringer Ingelheim Investigational Site 767

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bruchweiler-Baerenbach : Boehringer Ingelheim Investigational Site 407

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchbach : Boehringer Ingelheim Investigational Site 321

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchbach : Boehringer Ingelheim Investigational Site 322

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchholz : Boehringer Ingelheim Investigational Site 1007

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchholz : Boehringer Ingelheim Investigational Site 1038

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buckow : Boehringer Ingelheim Investigational Site 1277

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buechen : Boehringer Ingelheim Investigational Site 1439

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buechen : Boehringer Ingelheim Investigational Site 1096

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buechen : Boehringer Ingelheim Investigational Site 1095

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bueckeburg : Boehringer Ingelheim Investigational Site 927

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buende : Boehringer Ingelheim Investigational Site 837

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bueren : Boehringer Ingelheim Investigational Site 789

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burg (Spreewald) : Boehringer Ingelheim Investigational Site 1238

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burgdorf : Boehringer Ingelheim Investigational Site 939

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burgdorf : Boehringer Ingelheim Investigational Site 943

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burgneudorf : Boehringer Ingelheim Investigational Site 1372

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Butzbach : Boehringer Ingelheim Investigational Site 525

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop Rauxel : Boehringer Ingelheim Investigational Site 761

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop-Rauxel : Boehringer Ingelheim Investigational Site 773

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop-Rauxel : Boehringer Ingelheim Investigational Site 771

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop-Rauxel : Boehringer Ingelheim Investigational Site 785

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1197

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1203

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1184

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1200

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1201

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1202

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1204

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1183

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1185

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1186

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Coburg : Klinikum Coburg Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Coburg : Klinikum Coburg Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Coburg : Boehringer Ingelheim Investigational Site 385

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Coburg : Klinikum Coburg

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Cochem : Boehringer Ingelheim Investigational Site 452

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Coswig : Boehringer Ingelheim Investigational Site 1296

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Cottbus : Boehringer Ingelheim Investigational Site 1236

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Crinitz : Boehringer Ingelheim Investigational Site 1240

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dachau : Boehringer Ingelheim Investigational Site 285

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dachau : Boehringer Ingelheim Investigational Site 282

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Darmstadt : Boehringer Ingelheim Investigational Site 461

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Darmstadt : Boehringer Ingelheim Investigational Site 486

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Darmstadt : Boehringer Ingelheim Investigational Site 459

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dautphetal : Boehringer Ingelheim Investigational Site 561

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Deggendorf : Boehringer Ingelheim Investigational Site 338

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Delitzsch : Boehringer Ingelheim Investigational Site 1406

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Demmin : Boehringer Ingelheim Investigational Site 1139

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dessau-Rosslau : Boehringer Ingelheim Investigational Site 1298

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Detmold : Boehringer Ingelheim Investigational Site 852

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dieburg : Boehringer Ingelheim Investigational Site 497

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dieburg : Boehringer Ingelheim Investigational Site 496

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Diepenau : Boehringer Ingelheim Investigational Site 955

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Diessen : Boehringer Ingelheim Investigational Site 227

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dietzhoelztal : Boehringer Ingelheim Investigational Site 554

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dillingen/Saar : Boehringer Ingelheim Investigational Site 567

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinkelsbuehl : Boehringer Ingelheim Investigational Site 212

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinkelsbuehl : Boehringer Ingelheim Investigational Site 187

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinkelsbuehl : Boehringer Ingelheim Investigational Site 202

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinklage : Boehringer Ingelheim Investigational Site 984

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinslaken : Boehringer Ingelheim Investigational Site 689

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinslaken-Averbruch : Boehringer Ingelheim Investigational Site 723

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Doberan : Boehringer Ingelheim Investigational Site 1136

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Doerfles-Esbach : Boehringer Ingelheim Investigational Site 381

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dogern : Boehringer Ingelheim Investigational Site 20

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dormagen : Boehringer Ingelheim Investigational Site 665

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Dortmund : Boehringer Ingelheim Investigational Site 758

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 763

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 603

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 606

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 770

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 757

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 759

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 760

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 762

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 786

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dreieich : Boehringer Ingelheim Investigational Site 519

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dreieich-Dreieichenhain : Boehringer Ingelheim Investigational Site 521

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Praxisklinik Herz and Gefaesse Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Dresden : Boehringer Ingelheim Investigational Site 1367

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1383

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1351

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1381

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1382

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1352

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1368

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1369

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1370

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1371

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Praxisklinik - Herz- und Gefässe

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Dresden : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Driedorf : Boehringer Ingelheim Investigational Site 556

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Drochtersen : Boehringer Ingelheim Investigational Site 1048

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Drochtersen : Boehringer Ingelheim Investigational Site 1049

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dudenhofen : Boehringer Ingelheim Investigational Site 403

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 660

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 662

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 659

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 681

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 876

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 657

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 658

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 663

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 679

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 680

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 865

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 878

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 654

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf (Benrath) : Boehringer Ingelheim Investigational Site 877

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 702

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 703

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 695

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 700

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 693

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 694

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 705

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg (Walsum) : Boehringer Ingelheim Investigational Site 704

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Durach : Boehringer Ingelheim Investigational Site 222

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Durmersheim : Boehringer Ingelheim Investigational Site 33

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Düsseldorf : Evangelisches Krankenhaus Düsseldorf Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Ebeleben : Boehringer Ingelheim Investigational Site 1158

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ebergoetzen : Boehringer Ingelheim Investigational Site 923

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ebersburg-Schmalnau : Boehringer Ingelheim Investigational Site 548

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eckernfoerde : Boehringer Ingelheim Investigational Site 1069

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eckernfoerde : Boehringer Ingelheim Investigational Site 1059

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Edewecht : Boehringer Ingelheim Investigational Site 970

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Edling : Boehringer Ingelheim Investigational Site 262

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Efringen-Kirchen : Boehringer Ingelheim Investigational Site 18

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ehingen : Boehringer Ingelheim Investigational Site 83

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ehrenkirchen : Boehringer Ingelheim Investigational Site 25

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ehringshausen : Boehringer Ingelheim Investigational Site 504

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eichstaett : Boehringer Ingelheim Investigational Site 189

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eilenburg : Boehringer Ingelheim Investigational Site 1422

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Einbeck : Boehringer Ingelheim Investigational Site 922

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ellwangen/Jagst : Boehringer Ingelheim Investigational Site 145

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elsterwerda : Boehringer Ingelheim Investigational Site 1244

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elsterwerda : Boehringer Ingelheim Investigational Site 1216

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elsterwerda : Boehringer Ingelheim Investigational Site 1218

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elz : Boehringer Ingelheim Investigational Site 446

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Engelskirchen-Ruenderoth : Boehringer Ingelheim Investigational Site 640

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ennigerloh-Ostenfelde : Boehringer Ingelheim Investigational Site 840

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eppelborn : Boehringer Ingelheim Investigational Site 582

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eppingen : Boehringer Ingelheim Investigational Site 132

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erfde : Boehringer Ingelheim Investigational Site 1086

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erftstadt : Boehringer Ingelheim Investigational Site 649

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erftstadt : Boehringer Ingelheim Investigational Site 651

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erfurt : Boehringer Ingelheim Investigational Site 1157

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erkelenz : Boehringer Ingelheim Investigational Site 619

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Erlangen : Boehringer Ingelheim Investigational Site 182

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 183

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 179

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 209

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 201

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 210

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 180

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erligheim : Boehringer Ingelheim Investigational Site 124

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eschborn : Boehringer Ingelheim Investigational Site 503

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eschwege : Boehringer Ingelheim Investigational Site 535

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eschweiler : Boehringer Ingelheim Investigational Site 591

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Espelkamp : Boehringer Ingelheim Investigational Site 857

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 708

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 710

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 715

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 716

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 690

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 707

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 709

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 711

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 712

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 713

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 714

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 701

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 691

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Universitätsklinikum Essen

DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.

Essen : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Esslingen : Boehringer Ingelheim Investigational Site 139

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ettlingen : Boehringer Ingelheim Investigational Site 35

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Euskirchen : Boehringer Ingelheim Investigational Site 648

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eutin : Boehringer Ingelheim Investigational Site 1074

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Falkensee : Boehringer Ingelheim Investigational Site 1337

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fassberg : Boehringer Ingelheim Investigational Site 938

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Felsberg-Gensungen : Boehringer Ingelheim Investigational Site 541

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 1058

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 1060

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 1083

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 1057

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Floeha : Boehringer Ingelheim Investigational Site 1356

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Florstadt / Staden : Boehringer Ingelheim Investigational Site 516

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Forchheim : Boehringer Ingelheim Investigational Site 1430

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Forchheim : Boehringer Ingelheim Investigational Site 1429

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankenberg : Boehringer Ingelheim Investigational Site 553

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : CCB - Cardioaniologisches Centrum Bethanien Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Frankfurt : Boehringer Ingelheim Investigational Site 492

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : Boehringer Ingelheim Investigational Site 494

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : Boehringer Ingelheim Investigational Site 488

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Frankfurt : Cardioangiologisches Centrum Bethanien - CCB

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Frankfurt (Oder) : Boehringer Ingelheim Investigational Site 1227

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt am Main : Boehringer Ingelheim Investigational Site 517

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/M. : Boehringer Ingelheim Investigational Site 491

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/M. : Boehringer Ingelheim Investigational Site 518

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/Oder : Boehringer Ingelheim Investigational Site 1219

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/Oder : Boehringer Ingelheim Investigational Site 1228

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frechen : Boehringer Ingelheim Investigational Site 602

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiberg : Boehringer Ingelheim Investigational Site 1366

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiberg : Boehringer Ingelheim Investigational Site 1355

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 1

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 5

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 6

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 24

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 23

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freinsheim : Boehringer Ingelheim Investigational Site 410

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freising : Boehringer Ingelheim Investigational Site 278

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freital : Boehringer Ingelheim Investigational Site 1363

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fremdingen : Boehringer Ingelheim Investigational Site 190

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frensdorf : Boehringer Ingelheim Investigational Site 361

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Friedrichshafen : Boehringer Ingelheim Investigational Site 101

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fritzlar : Boehringer Ingelheim Investigational Site 527

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Froendenberg : Boehringer Ingelheim Investigational Site 781

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Froendenberg : Boehringer Ingelheim Investigational Site 768

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Froendenberg : Boehringer Ingelheim Investigational Site 783

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenfeldbruck : Boehringer Ingelheim Investigational Site 326

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenfeldbruck-Aich : Boehringer Ingelheim Investigational Site 324

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenwalde/Spree : Boehringer Ingelheim Investigational Site 1233

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenwalde/Spree : Boehringer Ingelheim Investigational Site 1232

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerth : Boehringer Ingelheim Investigational Site 358

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fulda : Boehringer Ingelheim Investigational Site 537

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gangkofen : Boehringer Ingelheim Investigational Site 353

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Garching : Boehringer Ingelheim Investigational Site 308

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gardelegen : Boehringer Ingelheim Investigational Site 1315

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Garmisch-Partenkirchen : Boehringer Ingelheim Investigational Site 226

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Garmisch-Patenkirchen : Boehringer Ingelheim Investigational Site 237

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gedern-Wenings : Boehringer Ingelheim Investigational Site 524

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geeste : Boehringer Ingelheim Investigational Site 981

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geisenkirchen-Buer : Boehringer Ingelheim Investigational Site 798

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geislingen/Steige : Boehringer Ingelheim Investigational Site 80

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geislingen/Steige : Boehringer Ingelheim Investigational Site 90

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 801

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 818

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 822

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 824

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 804

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 797

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 821

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 823

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gensingen : Boehringer Ingelheim Investigational Site 469

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Genthin : Boehringer Ingelheim Investigational Site 1281

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Genthin : Boehringer Ingelheim Investigational Site 1282

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gera : Boehringer Ingelheim Investigational Site 1181

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gera : Boehringer Ingelheim Investigational Site 1180

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geretsried : Boehringer Ingelheim Investigational Site 251

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gerlingen : Boehringer Ingelheim Investigational Site 39

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Germersheim : Boehringer Ingelheim Investigational Site 396

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gersfeld : Boehringer Ingelheim Investigational Site 560

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gerstetten : Boehringer Ingelheim Investigational Site 88

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giengen : Boehringer Ingelheim Investigational Site 78

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giessen : Boehringer Ingelheim Investigational Site 528

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giessen : Boehringer Ingelheim Investigational Site 529

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gifhorn : Boehringer Ingelheim Investigational Site 901

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gilching : Boehringer Ingelheim Investigational Site 235

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Glindow : Boehringer Ingelheim Investigational Site 1333

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gluecksburg : Boehringer Ingelheim Investigational Site 1087

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goerlitz : Boehringer Ingelheim Investigational Site 1379

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goerlitz : Boehringer Ingelheim Investigational Site 1358

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goerlitz : Boehringer Ingelheim Investigational Site 1359

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goettingen : Universitätsmedizin Göttingen (UMG), Kardiologie und Pneumologie

Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion

Goettingen-Weende : Boehringer Ingelheim Investigational Site 925

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goldberg : Boehringer Ingelheim Investigational Site 1132

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Göttingen : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Graefelfing : Boehringer Ingelheim Investigational Site 256

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Graefenhainichen : Boehringer Ingelheim Investigational Site 1401

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grafenrheinfeld : Boehringer Ingelheim Investigational Site 194

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Greifswald : Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Griesheim : Boehringer Ingelheim Investigational Site 481

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grimmen : Boehringer Ingelheim Investigational Site 1141

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grossefehn : Boehringer Ingelheim Investigational Site 976

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gross-Groenau : Boehringer Ingelheim Investigational Site 1078

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grossrosseln : Boehringer Ingelheim Investigational Site 570

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gross-Zimmern : Boehringer Ingelheim Investigational Site 520

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gruenstadt : Boehringer Ingelheim Investigational Site 394

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guenzburg : Boehringer Ingelheim Investigational Site 289

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guetersloh : Boehringer Ingelheim Investigational Site 845

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guetersloh : Boehringer Ingelheim Investigational Site 846

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guetersloh : Boehringer Ingelheim Investigational Site 850

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gummersbach : Boehringer Ingelheim Investigational Site 624

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gundelfingen : Boehringer Ingelheim Investigational Site 17

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haan : Boehringer Ingelheim Investigational Site 862

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haan : Boehringer Ingelheim Investigational Site 873

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haar : Boehringer Ingelheim Investigational Site 260

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hachenburg : Boehringer Ingelheim Investigational Site 420

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hadamar : Boehringer Ingelheim Investigational Site 451

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 724

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 731

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 744

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 745

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 747

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 748

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 725

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haibach : Boehringer Ingelheim Investigational Site 198

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haibach : Boehringer Ingelheim Investigational Site 1442

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halberstadt : Boehringer Ingelheim Investigational Site 1310

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halberstadt : Boehringer Ingelheim Investigational Site 1288

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haldensleben : Boehringer Ingelheim Investigational Site 1291

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hallbergmoos : Boehringer Ingelheim Investigational Site 279

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1294

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 841

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1292

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1293

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1314

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1299

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1297

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 825

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 826

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 827

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle (Saale) : Boehringer Ingelheim Investigational Site 1300

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hallstadt : Boehringer Ingelheim Investigational Site 1435

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Hamburg : ASKLEPIOS KLINIK St. Georg

Alster Man and Machine: Comparison of Manual and Mechanical Remote Robotic Catheter Ablation for Drug-Refractory Atrial Fibrillation

Hamburg : Asklepios Klinik St. Georg

Alster-Lost-AF-Study

Hamburg : Universitäres Herzzentrum Hamburg GmbH / UKE Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Hamburg : Asklepios Klinik St. Georg Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Hamburg : University Hospital Eppendorf

CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study

Hamburg : Asklepios Klinik St. Georg Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Universitares Herrzentrum Hamburg Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Asklepios Klinik Barmbek Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Boehringer Ingelheim Investigational Site 1112

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1116

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1118

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1014

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1098

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1099

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1047

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1050

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1051

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1053

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1071

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1443

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1072

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1097

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1104

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1105

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1061

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1062

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1063

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1064

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1045

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1046

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1052

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1054

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1010

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1011

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1012

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1013

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1015

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1111

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Klinik St. Georg

European Carto XP Registry for Validating Specialized CFAE Software

Hamburg : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hamburg : Asklepios Klinik St. Georg

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Hamburg : Universitätskrankenhaus Eppendorf

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Hamburg-Bergstedt : Boehringer Ingelheim Investigational Site 1101

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hameln : Boehringer Ingelheim Investigational Site 945

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamm : Boehringer Ingelheim Investigational Site 756

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamm : Boehringer Ingelheim Investigational Site 782

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamm : Boehringer Ingelheim Investigational Site 777

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hammelburg : Boehringer Ingelheim Investigational Site 216

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanau : Boehringer Ingelheim Investigational Site 515

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanau am Main : Boehringer Ingelheim Investigational Site 511

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanau/M. : Boehringer Ingelheim Investigational Site 513

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hannover : Boehringer Ingelheim Investigational Site 940

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hannover : Boehringer Ingelheim Investigational Site 936

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hannover : Boehringer Ingelheim Investigational Site 958

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanstedt : Boehringer Ingelheim Investigational Site 1008

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanstedt : Boehringer Ingelheim Investigational Site 1044

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Harsewinkel : Boehringer Ingelheim Investigational Site 830

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haseluenne : Boehringer Ingelheim Investigational Site 980

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hassloch : Boehringer Ingelheim Investigational Site 389

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hassloch : Boehringer Ingelheim Investigational Site 412

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hausham : Boehringer Ingelheim Investigational Site 230

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Havixbeck : Boehringer Ingelheim Investigational Site 807

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heddesheim : Boehringer Ingelheim Investigational Site 121

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Klinikum der Ruprecht-Karls-Universität Heidelberg Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Heidelberg : Boehringer Ingelheim Investigational Site 110

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 103

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 115

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 111

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 106

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Department of Cardiology, University of Heidelberg

Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter

Heidelberg (Handschuhsheim) : Boehringer Ingelheim Investigational Site 120

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidenheim : Boehringer Ingelheim Investigational Site 71

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 128

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 131

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 113

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 125

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 126

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heiligenstadt : Boehringer Ingelheim Investigational Site 1161

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilstedt : Boehringer Ingelheim Investigational Site 1307

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heimstetten : Boehringer Ingelheim Investigational Site 298

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heinsberg : Boehringer Ingelheim Investigational Site 601

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heist : Boehringer Ingelheim Investigational Site 1093

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hellenthal : Boehringer Ingelheim Investigational Site 643

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Helmstedt : Boehringer Ingelheim Investigational Site 905

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Helmstedt : Boehringer Ingelheim Investigational Site 903

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 1028

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 1032

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 1027

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hennef : Boehringer Ingelheim Investigational Site 634

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hennef : Boehringer Ingelheim Investigational Site 630

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hennickendorf : Boehringer Ingelheim Investigational Site 1276

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Henstedt-Ulzburg : Boehringer Ingelheim Investigational Site 388

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Henstedt-Ulzburg : Boehringer Ingelheim Investigational Site 368

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hensted-Ulzburg : Boehringer Ingelheim Investigational Site 1070

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herbsleben : Boehringer Ingelheim Investigational Site 1154

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herford : Boehringer Ingelheim Investigational Site 832

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herford : Boehringer Ingelheim Investigational Site 836

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herne : Boehringer Ingelheim Investigational Site 819

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herne : Boehringer Ingelheim Investigational Site 820

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herne : Boehringer Ingelheim Investigational Site 1441

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herrenberg : Boehringer Ingelheim Investigational Site 36

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herrenberg-Affstaett : Boehringer Ingelheim Investigational Site 59

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herrnhut : Boehringer Ingelheim Investigational Site 1376

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heubach : Boehringer Ingelheim Investigational Site 153

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heusweiler : Boehringer Ingelheim Investigational Site 584

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heusweiler : Boehringer Ingelheim Investigational Site 587

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hilden : Boehringer Ingelheim Investigational Site 861

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hildesheim : Boehringer Ingelheim Investigational Site 919

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hilpoltstein : Boehringer Ingelheim Investigational Site 206

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hirschaid : Boehringer Ingelheim Investigational Site 270

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hirschaid : Boehringer Ingelheim Investigational Site 1431

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hirschau : Boehringer Ingelheim Investigational Site 346

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hochheim am Main : Boehringer Ingelheim Investigational Site 456

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoechberg : Boehringer Ingelheim Investigational Site 176

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoechberg : Boehringer Ingelheim Investigational Site 177

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoetensleben : Boehringer Ingelheim Investigational Site 1311

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohen Neuendorf/OT Bergfelde : Boehringer Ingelheim Investigational Site 1255

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohenau : Boehringer Ingelheim Investigational Site 354

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohenhameln : Boehringer Ingelheim Investigational Site 914

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohenleipisch : Boehringer Ingelheim Investigational Site 1241

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoisdorf : Boehringer Ingelheim Investigational Site 1100

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Holm : Boehringer Ingelheim Investigational Site 1067

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Horb : Boehringer Ingelheim Investigational Site 46

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoyerswerda : Boehringer Ingelheim Investigational Site 1375

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hude/Wuesting : Boehringer Ingelheim Investigational Site 983

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hueckelhoven : Boehringer Ingelheim Investigational Site 622

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Huerth : Boehringer Ingelheim Investigational Site 632

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hummeltal : Boehringer Ingelheim Investigational Site 380

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ibbenbueren-Dickenberg : Boehringer Ingelheim Investigational Site 811

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Idar-Oberstein : Boehringer Ingelheim Investigational Site 427

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingelheim : Boehringer Ingelheim Investigational Site 466

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingersheim : Boehringer Ingelheim Investigational Site 130

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Klinikum Ingolstadt GmbH Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Ingolstadt : Boehringer Ingelheim Investigational Site 185

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Boehringer Ingelheim Investigational Site 203

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Boehringer Ingelheim Investigational Site 204

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Boehringer Ingelheim Investigational Site 271

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Klinikum Ingolstadt GmbH

DEtermining Accuracy and TrEnding CharacTerization of AF

Irsch/Saar : Boehringer Ingelheim Investigational Site 588

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Iserlohn : Boehringer Ingelheim Investigational Site 749

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ismaning : Boehringer Ingelheim Investigational Site 316

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Issum : Boehringer Ingelheim Investigational Site 675

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jahnsdorf/Erzgeb. : Boehringer Ingelheim Investigational Site 1199

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jena : Boehringer Ingelheim Investigational Site 1192

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jena : Boehringer Ingelheim Investigational Site 1179

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jena-Lobeda : Boehringer Ingelheim Investigational Site 1193

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jettingen-Unterjettingen : Boehringer Ingelheim Investigational Site 62

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Johannesberg : Boehringer Ingelheim Investigational Site 195

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juebek : Boehringer Ingelheim Investigational Site 1085

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juechen : Boehringer Ingelheim Investigational Site 676

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juelich : Boehringer Ingelheim Investigational Site 590

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juenkerath : Boehringer Ingelheim Investigational Site 574

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaebschuetztal/OT Kroegis : Boehringer Ingelheim Investigational Site 1365

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kahl : Boehringer Ingelheim Investigational Site 193

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 399

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 400

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 398

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 406

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 409

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kalkar : Boehringer Ingelheim Investigational Site 674

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kamen : Boehringer Ingelheim Investigational Site 776

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kamen : Boehringer Ingelheim Investigational Site 772

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kamp-Lintfort : Boehringer Ingelheim Investigational Site 721

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kappeln : Boehringer Ingelheim Investigational Site 1084

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Saint Vincentius-Kliniken Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Karlsruhe : Boehringer Ingelheim Investigational Site 14

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 15

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 16

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 2

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Stadtisches Klinikum Karlsruhe

European Carto XP Registry for Validating Specialized CFAE Software

Karlsruhe (Durlach) : Boehringer Ingelheim Investigational Site 13

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 534

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 533

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 536

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempen : Boehringer Ingelheim Investigational Site 669

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempten : Boehringer Ingelheim Investigational Site 218

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempten : Boehringer Ingelheim Investigational Site 219

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempten : Boehringer Ingelheim Investigational Site 220

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kenzingen : Boehringer Ingelheim Investigational Site 30

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiedrich : Boehringer Ingelheim Investigational Site 471

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiel : Boehringer Ingelheim Investigational Site 1082

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiel : Boehringer Ingelheim Investigational Site 1055

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiel : Boehringer Ingelheim Investigational Site 1056

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kierspe : Boehringer Ingelheim Investigational Site 753

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kippenheim : Boehringer Ingelheim Investigational Site 29

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchardt : Boehringer Ingelheim Investigational Site 136

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchardt : Boehringer Ingelheim Investigational Site 135

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchenlamitz : Boehringer Ingelheim Investigational Site 347

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchheilingen : Boehringer Ingelheim Investigational Site 1153

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchheimbolanden : Boehringer Ingelheim Investigational Site 411

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchheimbolanden : Boehringer Ingelheim Investigational Site 413

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchzarten : Boehringer Ingelheim Investigational Site 4

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kleinmachnow : Boehringer Ingelheim Investigational Site 1319

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Klettgau-Griessen : Boehringer Ingelheim Investigational Site 55

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Klingenberg : Boehringer Ingelheim Investigational Site 192

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Klingenthal : Boehringer Ingelheim Investigational Site 1208

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 635

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 638

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 639

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 600

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 612

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 616

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 620

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 625

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 626

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 599

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 621

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 627

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 611

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 595

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 596

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 597

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 631

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln (Bilderstoeckchen) : Boehringer Ingelheim Investigational Site 613

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln-Hoehenberg : Boehringer Ingelheim Investigational Site 641

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln-Junkersdorf : Boehringer Ingelheim Investigational Site 598

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln-Lindenthal : Boehringer Ingelheim Investigational Site 615

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koenigsbrueck : Boehringer Ingelheim Investigational Site 1353

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koenigsbrunn : Boehringer Ingelheim Investigational Site 319

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koethen : Boehringer Ingelheim Investigational Site 1313

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koethen : Boehringer Ingelheim Investigational Site 1284

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Konstanz : Herz-Zentrum-Bodensee Konstanz

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Korschenbroich : Boehringer Ingelheim Investigational Site 678

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 670

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 661

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 656

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 673

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kreuztal : Boehringer Ingelheim Investigational Site 730

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronach : Boehringer Ingelheim Investigational Site 377

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronberg/Ts : Boehringer Ingelheim Investigational Site 507

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronberg/Ts. : Boehringer Ingelheim Investigational Site 508

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronshagen : Boehringer Ingelheim Investigational Site 1107

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronshagen : Boehringer Ingelheim Investigational Site 1108

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krumbach : Boehringer Ingelheim Investigational Site 310

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kuenzing : Boehringer Ingelheim Investigational Site 337

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

L.-Echterdingen : Boehringer Ingelheim Investigational Site 37

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laaber : Boehringer Ingelheim Investigational Site 349

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laage : Boehringer Ingelheim Investigational Site 1124

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laatzen : Boehringer Ingelheim Investigational Site 960

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laboe : Boehringer Ingelheim Investigational Site 1077

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lahnau : Boehringer Ingelheim Investigational Site 510

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laichingen : Boehringer Ingelheim Investigational Site 86

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lalendorf : Boehringer Ingelheim Investigational Site 1137

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lampertheim : Boehringer Ingelheim Investigational Site 463

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lampertheim : Boehringer Ingelheim Investigational Site 484

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lampertheim : Boehringer Ingelheim Investigational Site 480

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Landau : Boehringer Ingelheim Investigational Site 395

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Landshut : Krankenhaus Landshut-Achdorf Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Landshut : Boehringer Ingelheim Investigational Site 307

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenau : Boehringer Ingelheim Investigational Site 87

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenfeld : Boehringer Ingelheim Investigational Site 874

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenhagen : Boehringer Ingelheim Investigational Site 957

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenlonsheim : Boehringer Ingelheim Investigational Site 445

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauenburg : Boehringer Ingelheim Investigational Site 1113

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauf : Boehringer Ingelheim Investigational Site 365

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauscha : Boehringer Ingelheim Investigational Site 1166

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauterbach : Boehringer Ingelheim Investigational Site 551

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lebus : Boehringer Ingelheim Investigational Site 1274

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leck : Boehringer Ingelheim Investigational Site 1081

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leer : Boehringer Ingelheim Investigational Site 971

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lehrte : Boehringer Ingelheim Investigational Site 941

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leiblfing : Boehringer Ingelheim Investigational Site 242

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leinfelden-Echterdingen : Boehringer Ingelheim Investigational Site 43

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipheim : Boehringer Ingelheim Investigational Site 314

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Herzzentrum Leipzig GmbH Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Leipzig : Herzzentrum Leipzig Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Leipzig : Boehringer Ingelheim Investigational Site 1411

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1402

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1404

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1405

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1398

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1403

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1407

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1395

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1419

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1410

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1412

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Herzzentrum Leipzig GmbH

Ventricular Wall Motion Characterization

Lemwerder : Boehringer Ingelheim Investigational Site 978

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lengede-Woltwiesche : Boehringer Ingelheim Investigational Site 915

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lengerich : Boehringer Ingelheim Investigational Site 796

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lengerich : Boehringer Ingelheim Investigational Site 792

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : Boehringer Ingelheim Investigational Site 879

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : Boehringer Ingelheim Investigational Site 880

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : Boehringer Ingelheim Investigational Site 870

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lichtenfels : Boehringer Ingelheim Investigational Site 382

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lichtentanne : Boehringer Ingelheim Investigational Site 1195

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Liebenau : Boehringer Ingelheim Investigational Site 545

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lienen-Kattenvenne : Boehringer Ingelheim Investigational Site 808

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lienen-Kattenvenne : Boehringer Ingelheim Investigational Site 794

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lilienthal : Boehringer Ingelheim Investigational Site 1003

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Limburgerhof : Boehringer Ingelheim Investigational Site 405

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Limburgerhof : Boehringer Ingelheim Investigational Site 401

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindhorst : Boehringer Ingelheim Investigational Site 935

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindlar : Boehringer Ingelheim Investigational Site 629

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindlar : Boehringer Ingelheim Investigational Site 628

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Linnich : Boehringer Ingelheim Investigational Site 617

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Loerrach : Boehringer Ingelheim Investigational Site 8

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lohfelden : Boehringer Ingelheim Investigational Site 542

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lohne : Boehringer Ingelheim Investigational Site 985

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lollar : Boehringer Ingelheim Investigational Site 557

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lu.-Ruchheim : Boehringer Ingelheim Investigational Site 416

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lucka : Boehringer Ingelheim Investigational Site 1213

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luckau : Boehringer Ingelheim Investigational Site 1234

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luckenwalde : Boehringer Ingelheim Investigational Site 1345

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 156

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 140

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 164

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 165

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 166

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 172

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigshafen : Klinikum der Stadt Ludwigshafen am Rhein gGmbH Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Ludwigshafen : Boehringer Ingelheim Investigational Site 393

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigshafen : Boehringer Ingelheim Investigational Site 402

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigslust : Boehringer Ingelheim Investigational Site 1123

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebben : Boehringer Ingelheim Investigational Site 1235

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebeck : Boehringer Ingelheim Investigational Site 1073

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebeck : Boehringer Ingelheim Investigational Site 1106

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 750

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 754

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 755

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 735

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lueneburg : Boehringer Ingelheim Investigational Site 1035

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lueneburg : Boehringer Ingelheim Investigational Site 1037

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lueneburg : Boehringer Ingelheim Investigational Site 1039

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luetzen : Boehringer Ingelheim Investigational Site 1420

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luetzow : Boehringer Ingelheim Investigational Site 1130

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lutherstadt Wittenberg : Boehringer Ingelheim Investigational Site 1399

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lutzerath : Boehringer Ingelheim Investigational Site 425

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Maerkische Heide/ Gross Leuthen : Boehringer Ingelheim Investigational Site 1440

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Maerkische Heide/Gross Leuthen : Boehringer Ingelheim Investigational Site 1245

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : Boehringer Ingelheim Investigational Site 1283

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : Boehringer Ingelheim Investigational Site 1445

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : Boehringer Ingelheim Investigational Site 1289

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : University Hospital Magdeburg; Div. of Cardiology

Irbesartan and Adhesion Molecules in AF

Mainaschaff : Boehringer Ingelheim Investigational Site 196

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainburg : Boehringer Ingelheim Investigational Site 318

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 470

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 464

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 465

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Malterdingen : Boehringer Ingelheim Investigational Site 31

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : University Hospital of Mannheim Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Mannheim : Boehringer Ingelheim Investigational Site 108

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 109

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 105

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 114

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 119

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 117

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim (Almenhof) : Boehringer Ingelheim Investigational Site 116

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim (Kaefertal) : Boehringer Ingelheim Investigational Site 123

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim (Neuostheim) : Boehringer Ingelheim Investigational Site 122

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim (Waldhof) : Boehringer Ingelheim Investigational Site 118

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Marburg : Boehringer Ingelheim Investigational Site 530

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Margetshoechheim : Boehringer Ingelheim Investigational Site 181

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Markkleeberg : Boehringer Ingelheim Investigational Site 1393

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Markkleeberg : Boehringer Ingelheim Investigational Site 1394

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Markkleeberg : Boehringer Ingelheim Investigational Site 1418

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Markneukirchen : Boehringer Ingelheim Investigational Site 1210

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Marktheidenfeld : Boehringer Ingelheim Investigational Site 197

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Marktleugast : Boehringer Ingelheim Investigational Site 378

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Marktredwitz : Boehringer Ingelheim Investigational Site 328

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Marl : Boehringer Ingelheim Investigational Site 802

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Marl : Boehringer Ingelheim Investigational Site 813

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meckenheim : Boehringer Ingelheim Investigational Site 415

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meckenheim : Boehringer Ingelheim Investigational Site 642

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meeder : Boehringer Ingelheim Investigational Site 386

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meerbusch : Boehringer Ingelheim Investigational Site 655

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meerbusch : Boehringer Ingelheim Investigational Site 677

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meinerzhagen : Boehringer Ingelheim Investigational Site 752

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meiningen : Boehringer Ingelheim Investigational Site 1176

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meissen : Boehringer Ingelheim Investigational Site 1385

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meissen : Boehringer Ingelheim Investigational Site 1362

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Melle : Boehringer Ingelheim Investigational Site 990

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Melle : Boehringer Ingelheim Investigational Site 988

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Melsungen : Boehringer Ingelheim Investigational Site 526

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Memmelsdorf-Drosendorf : Boehringer Ingelheim Investigational Site 1427

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Memmelsdorf-Drosendorf : Boehringer Ingelheim Investigational Site 362

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Menden : Boehringer Ingelheim Investigational Site 746

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mending : Boehringer Ingelheim Investigational Site 440

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Merseburg : Boehringer Ingelheim Investigational Site 1387

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Messkirch : Boehringer Ingelheim Investigational Site 93

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mettingen : Boehringer Ingelheim Investigational Site 810

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Metzingen : Boehringer Ingelheim Investigational Site 70

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Michelau : Boehringer Ingelheim Investigational Site 366

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Milower Land : Boehringer Ingelheim Investigational Site 1338

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Milower Land : Boehringer Ingelheim Investigational Site 1339

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Miltenberg : Boehringer Ingelheim Investigational Site 178

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 838

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 834

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 856

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 851

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 848

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 847

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mittweida : Boehringer Ingelheim Investigational Site 1386

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 666

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 682

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 683

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 684

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 685

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 667

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moers : Boehringer Ingelheim Investigational Site 696

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moers : Boehringer Ingelheim Investigational Site 699

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moers : Boehringer Ingelheim Investigational Site 722

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moessingen : Boehringer Ingelheim Investigational Site 45

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Molfsee : Boehringer Ingelheim Investigational Site 1089

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mönchengladbach : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Monheim : Boehringer Ingelheim Investigational Site 872

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moormerland : Boehringer Ingelheim Investigational Site 973

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moormerland : Boehringer Ingelheim Investigational Site 977

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muehldorf : Boehringer Ingelheim Investigational Site 299

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muehldorf : Boehringer Ingelheim Investigational Site 272

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muehlhausen : Boehringer Ingelheim Investigational Site 1163

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muehlhausen : Boehringer Ingelheim Investigational Site 1150

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muelheim : Boehringer Ingelheim Investigational Site 720

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muelheim : Boehringer Ingelheim Investigational Site 717

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muelheim : Boehringer Ingelheim Investigational Site 719

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchberg : Boehringer Ingelheim Investigational Site 383

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 295

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 296

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 303

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 275

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 265

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 280

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 283

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 246

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 248

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 231

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 273

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 274

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 276

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 277

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 264

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 266

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 249

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 269

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 250

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 252

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 253

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 254

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 232

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 297

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 301

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 304

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 305

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 306

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 317

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenster : Boehringer Ingelheim Investigational Site 828

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenster : Boehringer Ingelheim Investigational Site 831

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

München : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

München : Klinikum Großhadern der Ludwig-Maximilians-Universität Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Munderkingen : Boehringer Ingelheim Investigational Site 81

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Munich : Isar Heart Center

DEtermining Accuracy and TrEnding CharacTerization of AF

Münster : Herzzentrum am Universitätsklinikum Münster Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Murrhardt : Boehringer Ingelheim Investigational Site 171

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nalbach : Boehringer Ingelheim Investigational Site 586

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nassau : Boehringer Ingelheim Investigational Site 450

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nauen : Boehringer Ingelheim Investigational Site 1335

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nauenstadt : Boehringer Ingelheim Investigational Site 151

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nersingen : Boehringer Ingelheim Investigational Site 294

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nersingen : Boehringer Ingelheim Investigational Site 292

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nettersheim : Boehringer Ingelheim Investigational Site 644

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nettersheim : Boehringer Ingelheim Investigational Site 652

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nettetal : Boehringer Ingelheim Investigational Site 671

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neubiberg : Boehringer Ingelheim Investigational Site 223

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neubrandenburg : Boehringer Ingelheim Investigational Site 360

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neubrandenburg : Boehringer Ingelheim Investigational Site 1126

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neubrandenburg : Boehringer Ingelheim Investigational Site 1128

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuburg : Boehringer Ingelheim Investigational Site 207

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuburg : Boehringer Ingelheim Investigational Site 184

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neudenau : Boehringer Ingelheim Investigational Site 174

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuhausen ob Eck : Boehringer Ingelheim Investigational Site 57

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuhof : Boehringer Ingelheim Investigational Site 547

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neukirchen Hl. Blut : Boehringer Ingelheim Investigational Site 341

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neumuenster : Boehringer Ingelheim Investigational Site 1090

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neumuenster : Boehringer Ingelheim Investigational Site 1091

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neunkirchen : Boehringer Ingelheim Investigational Site 562

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuried : Boehringer Ingelheim Investigational Site 234

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuruppin : Boehringer Ingelheim Investigational Site 1342

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuss : Boehringer Ingelheim Investigational Site 687

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuss : Boehringer Ingelheim Investigational Site 664

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuss : Boehringer Ingelheim Investigational Site 686

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuss-Holzheim : Boehringer Ingelheim Investigational Site 688

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt : Boehringer Ingelheim Investigational Site 1068

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt : Boehringer Ingelheim Investigational Site 549

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt : Boehringer Ingelheim Investigational Site 550

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt : Boehringer Ingelheim Investigational Site 934

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt/Weinstrasse : Boehringer Ingelheim Investigational Site 390

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neutraubling : Boehringer Ingelheim Investigational Site 351

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neu-Ulm : Boehringer Ingelheim Investigational Site 313

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neu-Ulm : Boehringer Ingelheim Investigational Site 293

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neu-Ulm : Boehringer Ingelheim Investigational Site 315

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuwied : Boehringer Ingelheim Investigational Site 428

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Niederkassel-Rheidt : Boehringer Ingelheim Investigational Site 637

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Niedernwoehren : Boehringer Ingelheim Investigational Site 929

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Niedernwoehren : Boehringer Ingelheim Investigational Site 948

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Niederwoerresbach : Boehringer Ingelheim Investigational Site 443

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nienburg : Boehringer Ingelheim Investigational Site 951

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Noerdlingen : Boehringer Ingelheim Investigational Site 205

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Norderstedt : Boehringer Ingelheim Investigational Site 1117

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Norderstedt : Boehringer Ingelheim Investigational Site 1115

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nordheim : Boehringer Ingelheim Investigational Site 127

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Northeim : Boehringer Ingelheim Investigational Site 892

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nossen : Boehringer Ingelheim Investigational Site 1350

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nossen : Boehringer Ingelheim Investigational Site 1364

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 1423

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 1424

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 355

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 357

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 372

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 374

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 356

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 363

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 375

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 376

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 370

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 371

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuertingen : Boehringer Ingelheim Investigational Site 162

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberdorla : Boehringer Ingelheim Investigational Site 1148

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberhausen : Boehringer Ingelheim Investigational Site 718

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberhausen : Boehringer Ingelheim Investigational Site 697

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberhausen : Boehringer Ingelheim Investigational Site 698

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberhausen : Boehringer Ingelheim Investigational Site 692

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Obernkirchen : Boehringer Ingelheim Investigational Site 946

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ober-Ramstadt : Boehringer Ingelheim Investigational Site 479

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberried : Boehringer Ingelheim Investigational Site 7

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Obertshausen-Hausen : Boehringer Ingelheim Investigational Site 523

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oelde : Boehringer Ingelheim Investigational Site 844

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oerel : Boehringer Ingelheim Investigational Site 1029

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oerel : Boehringer Ingelheim Investigational Site 1026

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oer-Erkenschwich : Boehringer Ingelheim Investigational Site 774

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oettingen : Boehringer Ingelheim Investigational Site 320

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Offenbach : Boehringer Ingelheim Investigational Site 495

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Offenbach : Boehringer Ingelheim Investigational Site 490

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Offenburg : Boehringer Ingelheim Investigational Site 27

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Olching/Neu-Esting : Boehringer Ingelheim Investigational Site 302

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oldenburg : Boehringer Ingelheim Investigational Site 967

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oranienburg : Boehringer Ingelheim Investigational Site 1256

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oranienburg : Boehringer Ingelheim Investigational Site 1269

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oranienburg : Boehringer Ingelheim Investigational Site 1266

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oschatz : Boehringer Ingelheim Investigational Site 1417

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oschersleben : Boehringer Ingelheim Investigational Site 1285

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oschersleben : Boehringer Ingelheim Investigational Site 1304

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Osloss : Boehringer Ingelheim Investigational Site 910

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ostercappeln : Boehringer Ingelheim Investigational Site 961

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Osterode : Boehringer Ingelheim Investigational Site 924

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ostrach : Boehringer Ingelheim Investigational Site 82

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ostseeheilbad Zingst : Boehringer Ingelheim Investigational Site 1144

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ottendorf : Boehringer Ingelheim Investigational Site 1033

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Otterbach : Boehringer Ingelheim Investigational Site 408

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Otterstadt : Boehringer Ingelheim Investigational Site 404

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ottobrunn : Boehringer Ingelheim Investigational Site 228

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ottobrunn : Boehringer Ingelheim Investigational Site 244

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Paderborn : St. Vincenz-Krankenhaus Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Paderborn : Boehringer Ingelheim Investigational Site 787

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Paderborn : Boehringer Ingelheim Investigational Site 765

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Paderborn : Boehringer Ingelheim Investigational Site 766

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 963

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 989

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 962

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 964

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 995

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 996

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Kardiologische Gemeinschaftspraxis

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Parchim : Boehringer Ingelheim Investigational Site 1129

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Passau : Boehringer Ingelheim Investigational Site 333

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Peine : Boehringer Ingelheim Investigational Site 909

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Peine : Boehringer Ingelheim Investigational Site 898

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Peine : Boehringer Ingelheim Investigational Site 897

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Penzberg : Boehringer Ingelheim Investigational Site 229

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Penzberg : Boehringer Ingelheim Investigational Site 255

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Penzberg : Boehringer Ingelheim Investigational Site 236

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pforzheim : Boehringer Ingelheim Investigational Site 138

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pforzheim : Boehringer Ingelheim Investigational Site 49

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pforzheim : Boehringer Ingelheim Investigational Site 51

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pfullingen : Boehringer Ingelheim Investigational Site 94

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pfungstadt : Boehringer Ingelheim Investigational Site 483

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pirmasens : Boehringer Ingelheim Investigational Site 392

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pirna : Boehringer Ingelheim Investigational Site 1357

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pirna : Boehringer Ingelheim Investigational Site 1438

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plaidt : Boehringer Ingelheim Investigational Site 442

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Planegg : Boehringer Ingelheim Investigational Site 259

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plattling : Boehringer Ingelheim Investigational Site 335

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plauen : Boehringer Ingelheim Investigational Site 1182

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plauen : Boehringer Ingelheim Investigational Site 1198

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plauen : Boehringer Ingelheim Investigational Site 1209

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pleiskirchen : Boehringer Ingelheim Investigational Site 309

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ploen : Boehringer Ingelheim Investigational Site 1066

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pocking : Boehringer Ingelheim Investigational Site 352

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Poecking : Boehringer Ingelheim Investigational Site 257

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Polch : Boehringer Ingelheim Investigational Site 439

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1324

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1392

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1390

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1391

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1320

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1321

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1322

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1334

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pottenstein : Boehringer Ingelheim Investigational Site 384

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Preetz : Boehringer Ingelheim Investigational Site 1075

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Preetz : Boehringer Ingelheim Investigational Site 1065

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Premnitz : Boehringer Ingelheim Investigational Site 1340

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Prerow : Boehringer Ingelheim Investigational Site 1145

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Puettlingen : Boehringer Ingelheim Investigational Site 563

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Puettlingen : Boehringer Ingelheim Investigational Site 569

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pulheim-Brauweiler : Boehringer Ingelheim Investigational Site 614

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pullach : Boehringer Ingelheim Investigational Site 258

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pulsnitz : Boehringer Ingelheim Investigational Site 1378

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Putbus/Ruegen : Boehringer Ingelheim Investigational Site 1127

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Querfurt : Boehringer Ingelheim Investigational Site 1408

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rabenau-Londorf : Boehringer Ingelheim Investigational Site 558

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rabitz-Rosenthal : Boehringer Ingelheim Investigational Site 1380

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Radebeul : Boehringer Ingelheim Investigational Site 1354

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Radevormwald : Boehringer Ingelheim Investigational Site 869

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Radolfzell : Boehringer Ingelheim Investigational Site 48

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rastatt : Boehringer Ingelheim Investigational Site 11

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rastatt-Wintersdorf : Boehringer Ingelheim Investigational Site 10

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Raubach : Boehringer Ingelheim Investigational Site 417

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ravensburg : Boehringer Ingelheim Investigational Site 102

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Recke : Boehringer Ingelheim Investigational Site 793

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Recke : Boehringer Ingelheim Investigational Site 809

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Recklinghausen : Boehringer Ingelheim Investigational Site 800

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Regensburg : Boehringer Ingelheim Investigational Site 329

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Regensburg : Boehringer Ingelheim Investigational Site 350

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Regensburg : Boehringer Ingelheim Investigational Site 327

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reinbek : St. Adolf-Stift Reinbek Updated

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Remscheid : Boehringer Ingelheim Investigational Site 889

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Remscheid : Boehringer Ingelheim Investigational Site 890

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Remseck : Boehringer Ingelheim Investigational Site 157

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Remseck-Aldingen : Boehringer Ingelheim Investigational Site 159

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rennerod : Boehringer Ingelheim Investigational Site 433

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 163

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 142

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 161

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 141

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 143

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rheinberg : Boehringer Ingelheim Investigational Site 706

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rheinmuenster-Schwarzach : Boehringer Ingelheim Investigational Site 34

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rheinstetten : Boehringer Ingelheim Investigational Site 9

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rieden : Boehringer Ingelheim Investigational Site 454

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rieschweiler : Boehringer Ingelheim Investigational Site 414

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rietberg-Neuenkirchen : Boehringer Ingelheim Investigational Site 853

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rittmarshausen : Boehringer Ingelheim Investigational Site 926

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rodewisch : Boehringer Ingelheim Investigational Site 1207

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Roecknitz : Boehringer Ingelheim Investigational Site 1421

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Roederland-Proesen : Boehringer Ingelheim Investigational Site 1242

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Roedermark : Boehringer Ingelheim Investigational Site 522

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rohrberg : Boehringer Ingelheim Investigational Site 1290

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rosengarten : Boehringer Ingelheim Investigational Site 1042

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rosenheim : Boehringer Ingelheim Investigational Site 239

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rosenheim : Boehringer Ingelheim Investigational Site 245

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rostock : University of Rostock

BioMonitor Master Study

Rostock : Universitat Rostock Updated

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Rostock : Universitätsklinikum Rostock Updated

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Rostock : Boehringer Ingelheim Investigational Site 1135

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rostock : Boehringer Ingelheim Investigational Site 1120

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rotenburg : Boehringer Ingelheim Investigational Site 546

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rotenburg : Boehringer Ingelheim Investigational Site 1016

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rottach-Weissach : Boehringer Ingelheim Investigational Site 225

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rudersberg : Boehringer Ingelheim Investigational Site 155

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rudersdorf : Boehringer Ingelheim Investigational Site 1279

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ruppichteroth : Boehringer Ingelheim Investigational Site 636

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Saarbruecken : Boehringer Ingelheim Investigational Site 566

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Saarbruecken : Boehringer Ingelheim Investigational Site 583

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Saarbruecken : Boehringer Ingelheim Investigational Site 572

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Saarbruecken : Boehringer Ingelheim Investigational Site 585

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Saarlouis : Boehringer Ingelheim Investigational Site 565

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salching : Boehringer Ingelheim Investigational Site 243

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzatal : Boehringer Ingelheim Investigational Site 1286

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzatal : Boehringer Ingelheim Investigational Site 1287

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzatal/OT Schiepzig : Boehringer Ingelheim Investigational Site 1295

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzbergen : Boehringer Ingelheim Investigational Site 992

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzgitter (Lebenstedt) : Boehringer Ingelheim Investigational Site 916

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzgitter (Lebenstedt) : Boehringer Ingelheim Investigational Site 918

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzmuende : Boehringer Ingelheim Investigational Site 1301

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzmuende : Boehringer Ingelheim Investigational Site 1302

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzweg bei Passau : Boehringer Ingelheim Investigational Site 332

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sand : Boehringer Ingelheim Investigational Site 364

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sandesneben : Boehringer Ingelheim Investigational Site 1114

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sankt Augustin : Boehringer Ingelheim Investigational Site 653

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sarstedt : Boehringer Ingelheim Investigational Site 917

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schenefeld : Boehringer Ingelheim Investigational Site 387

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schlagsdorf : Boehringer Ingelheim Investigational Site 1147

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schleching : Boehringer Ingelheim Investigational Site 261

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schloss Holte-Stukenbrock : Boehringer Ingelheim Investigational Site 854

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schlotheim : Boehringer Ingelheim Investigational Site 1175

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schmalkalden : Boehringer Ingelheim Investigational Site 1165

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schmelz : Boehringer Ingelheim Investigational Site 564

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schneeberg : Boehringer Ingelheim Investigational Site 1205

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoemberg : Boehringer Ingelheim Investigational Site 68

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoenberg : Boehringer Ingelheim Investigational Site 1079

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoenberg/Meckl. : Boehringer Ingelheim Investigational Site 1146

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoenebeck : Boehringer Ingelheim Investigational Site 1303

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoensee : Boehringer Ingelheim Investigational Site 1437

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoensee : Boehringer Ingelheim Investigational Site 344

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoeppenstadt : Boehringer Ingelheim Investigational Site 907

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schopfheim : Boehringer Ingelheim Investigational Site 22

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schopfheim : Boehringer Ingelheim Investigational Site 26

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schorndorf : Boehringer Ingelheim Investigational Site 154

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schorndorf : Boehringer Ingelheim Investigational Site 173

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schorndorf : Boehringer Ingelheim Investigational Site 167

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schortens : Boehringer Ingelheim Investigational Site 968

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schramberg-Sulgen : Boehringer Ingelheim Investigational Site 38

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schramberg-Sulgen : Boehringer Ingelheim Investigational Site 60

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schriesheim : Boehringer Ingelheim Investigational Site 1094

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schutterwald : Boehringer Ingelheim Investigational Site 28

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwabhausen : Boehringer Ingelheim Investigational Site 325

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwaebisch Hall : Boehringer Ingelheim Investigational Site 144

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwaig b. Nbg. : Boehringer Ingelheim Investigational Site 284

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwarzenbach a. Wald : Boehringer Ingelheim Investigational Site 379

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwarzenbek : Boehringer Ingelheim Investigational Site 1444

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwarzenbruck : Boehringer Ingelheim Investigational Site 1425

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwerin : Boehringer Ingelheim Investigational Site 1122

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwerin : Boehringer Ingelheim Investigational Site 1119

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwerin : Boehringer Ingelheim Investigational Site 1142

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwerin : Boehringer Ingelheim Investigational Site 1121

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwieberdingen : Boehringer Ingelheim Investigational Site 66

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Seeg : Boehringer Ingelheim Investigational Site 221

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Seelow : Boehringer Ingelheim Investigational Site 1275

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sehnde : Boehringer Ingelheim Investigational Site 959

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sendenhorst : Boehringer Ingelheim Investigational Site 839

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Siegen : Boehringer Ingelheim Investigational Site 727

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Siegen : Boehringer Ingelheim Investigational Site 728

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Siegen : Boehringer Ingelheim Investigational Site 726

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Siegen : Boehringer Ingelheim Investigational Site 729

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Simmertal : Boehringer Ingelheim Investigational Site 444

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Atrial Fibrillation Clinical Trials

Alabama

Alaska

Arizona

Arkansas

California

Colorado

Connecticut

Delaware

District of Columbia

Florida

Georgia

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Montana

Nebraska

Nevada

New Jersey

New Mexico

New York

North Carolina

North Dakota

Ohio

Oklahoma

Oregon

Pennsylvania

South Carolina

South Dakota

Tennessee

Texas

Utah

Virginia

Washington

West Virginia

Wisconsin

Argentina

Australia

Austria

Belgium

Brazil

Canada

China

Colombia

Czech Republic

Denmark

Estonia

Finland

France

Germany